
About Shubham Pharmaceutical
Shubham Pharmaceutical is a publicly listed company based in Mumbai (India) founded in 2006. It serves as a distributor of a wide range of pharmaceutical drugs. It operates on a B2B model. Its Indian entity Sun Pharmaceutical Industries Limited reported revenue of ₹61,674 Cr. Its focus areas include Pharmaceuticals, Distribution and Drug Supply. Similar companies include Entero Healthcare, Keimed and Sandor Medicaids; 3 of its 3 listed similar companies have raised funding.
Company details
Shubham Pharmaceutical, founded in 2006 in Mumbai, India, focuses on providing healthcare solutions, producing pharmaceutical products, distribution, and drug supply. Serves as a distributor of a wide range of pharmaceutical drugs. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
- Headquarters Mumbai, India
- Stage Public
- SectorsHealthcare
- Website shubhampharma.com
- Legal Name Sun Pharmaceutical Industries Ltd., Therdose Pharma Private Limited
- Date of Incorporation 01 Mar, 1993
- Market Cap₹4,48,076 Cr
SUNPHARMA · NSE
- Share Price₹1,870.00
+0.13% today
- Revenue₹58,462 Cr
FY 2025-26 · +11.2% YoY
- EBITDA₹15,184 Cr
Margin 26.0%
- Net Profit₹12,429 Cr
FY 2025-26 · +8.5% YoY
- P/E (TTM)36.7x
P/B 5.1x
- ROE14.8%
ROCE 18.7%
- Debt / Equity0.04
Interest cover 2.8x
Associated legal entities of Shubham Pharmaceutical
Shubham Pharmaceutical operates through Sun Pharmaceutical Industries Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited Listed CIN L24230GJ1993PLC019050 | Active | 01 Mar 1993 | Vadodara, Gujarat | ₹61,674 Cr | 16,436 | 10 | View details |
Board of directors of Sun Pharmaceutical Industries Limited (Shubham Pharmaceutical)
Sun Pharmaceutical Industries Limited is the primary company behind Shubham Pharmaceutical. The board of Sun Pharmaceutical Industries Limited currently have 8 directors; the longest-serving is Dilip Shantilal Shanghvi, appointed in 2008. 20 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Dilip Shantilal Shanghvi DIN 00005588 | Whole-time director | 01 Apr 2008 | 18 yrs 7 mo | Sun Pharmaceutical Industries Limited |
| Pawan Kumar Goenka DIN 00254502 | Director | 21 May 2021 | 5 yrs 5 mo | Sun Pharmaceutical Industries Limited |
| Aalok Dilip Shanghvi DIN 01951829 | Whole-time director | 01 Jun 2023 | 3 yrs 5 mo | Sun Pharmaceutical Industries Limited |
| Rolf Karl Heinz Hoffmann DIN 10200311 | Director | 15 Jun 2023 | 3 yrs 5 mo | Sun Pharmaceutical Industries Limited |
| Vidhi Dilip Shanghvi DIN 06497350 | Whole-time director | 22 May 2025 | 1 yr 5 mo | Sun Pharmaceutical Industries Limited |
| Kirti Wardhaman Ganorkar DIN 10620142 | Managing Director | 01 Sep 2025 | 1 yr 2 mo | Sun Pharmaceutical Industries Limited |
| Satyavati Berera DIN 05002709 | Director | 08 May 2026 | 6 mo | Sun Pharmaceutical Industries Limited |
| Andreas Eugen Busch DIN 11699735 | Director | 12 May 2026 | 6 mo | Sun Pharmaceutical Industries Limited |
IPO & Listings of Shubham Pharmaceutical
Shubham Pharmaceutical is a publicly listed company on the NSE with ticker symbol SUNPHARMA in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNSE: SUNPHARMA
- Listed entitySun Pharmaceutical Industries Limited
- Exchange sectorPharmaceuticals
Financials of Shubham Pharmaceutical
Exchange-reported figures of Sun Pharmaceutical Industries Limited, the listed company behind Shubham Pharmaceutical (NSE: SUNPHARMA).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 58,462 | 52,578 | 48,497 | 43,886 | 38,654 | 33,498 | 32,838 |
| Revenue growth | +11.2% | +8.4% | +10.5% | +13.5% | +15.4% | +2.0% | - |
| EBITDA | 15,184 | 14,408 | 12,493 | 11,475 | 5,677 | 4,162 | 6,714 |
| EBITDA margin | +26.0% | +27.4% | +25.8% | +26.2% | +14.7% | +12.4% | +20.4% |
| Profit before tax | 15,119 | 13,752 | 11,088 | 9,408 | 4,481 | 2,799 | 5,010 |
| Net profit | 12,429 | 11,456 | 9,990 | 8,605 | 6,717 | 5,728 | 3,961 |
| Net profit margin | +21.3% | +21.8% | +20.6% | +19.6% | +17.4% | +17.1% | +12.1% |
| EPS (₹) | 47.84 | 45.55 | 39.91 | 35.32 | 13.64 | 12.10 | 15.69 |
| Balance sheet | |||||||
| Total assets | 90,020 | 75,718 | 71,314 | 67,131 | 53,376 | 54,447 | 58,774 |
| Net worth | 83,570 | 72,218 | 63,667 | 55,995 | 48,011 | 46,463 | 45,264 |
| Total debt | 4,627 | 2,362 | 3,274 | 6,886 | 1,290 | 3,869 | 8,315 |
| Cash & bank | 11,603 | 11,332 | 10,521 | 5,770 | 5,033 | 6,446 | 6,488 |
| Net working capital | 24,539 | 22,748 | 20,835 | 16,909 | 10,831 | 14,137 | 17,336 |
| Cash flow | |||||||
| Cash from operations | 12,419 | 14,072 | 12,135 | 4,959 | 8,985 | 6,170 | 6,555 |
| Cash from investing | (10,405) | (5,183) | (763) | (7,220) | (5,556) | 407 | (2,225) |
| Cash from financing | (2,513) | (7,906) | (6,710) | 2,376 | (5,193) | (5,980) | (5,715) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16,199 | 15,300 | 14,612 | 15,521 | 14,478 | 13,851 | 12,959 | 13,675 |
| Revenue growth (YoY) | +11.9% | +10.5% | +12.8% | +13.5% | +8.9% | +9.5% | - | - |
| Other income | 517 | 724 | 458 | 579 | 470 | 464 | 613 | 466 |
| EBITDA | 3,475 | 4,214 | 3,954 | 4,459 | 4,527 | 3,484 | 3,354 | 3,693 |
| EBITDA margin | +21.6% | +27.8% | +27.2% | +28.8% | +31.4% | +25.3% | +26.2% | +27.5% |
| Depreciation | 758 | 739 | 775 | 732 | 730 | 701 | 664 | 631 |
| Interest | 74.67 | 99.67 | 85.89 | 78.36 | 99.86 | 74.80 | 49.14 | 51.51 |
| Profit before tax | 3,159 | 4,099 | 3,551 | 4,227 | 4,168 | 3,173 | 3,254 | 3,476 |
| Tax | 1,158 | 1,188 | 828 | 826 | 1,031 | 870 | 1,094 | 559 |
| Net profit | 2,002 | 2,911 | 2,724 | 3,401 | 3,137 | 2,303 | 2,161 | 2,918 |
| EPS (₹) | 8.30 | 12.10 | 11.30 | 14.00 | 13.00 | 9.50 | 9.00 | 12.10 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 20,755 | 22,977 | 20,275 | 20,812 | 15,586 | 14,116 | 12,532 |
| Revenue growth | -9.7% | +13.3% | -2.6% | +33.5% | +10.4% | +12.6% | - |
| EBITDA | 4,277 | 6,583 | 5,281 | 3,485 | 848 | 2,167 | 2,712 |
| EBITDA margin | +20.6% | +28.7% | +26.1% | +16.7% | +5.4% | +15.4% | +21.6% |
| Profit before tax | 3,794 | 4,976 | 3,450 | 1,741 | 307 | 856 | 3,253 |
| Net profit | 2,945 | 4,218 | 3,052 | 3,356 | (1,338) | 906 | 3,018 |
| Net profit margin | +14.2% | +18.4% | +15.1% | +16.1% | -8.6% | +6.4% | +24.1% |
| EPS (₹) | 10.93 | 17.62 | 11.91 | 7.05 | (0.42) | 3.51 | 13.38 |
| Balance sheet | |||||||
| Total assets | 36,576 | 36,647 | 36,644 | 32,645 | 30,678 | 35,639 | 32,356 |
| Net worth | 22,371 | 23,900 | 23,694 | 23,748 | 24,588 | 26,938 | 24,396 |
| Total debt | 13,605 | 11,947 | 11,227 | 7,791 | 5,074 | 7,358 | 6,406 |
| Cash & bank | 437 | 911 | 338 | 421 | 535 | 361 | 655 |
| Net working capital | 10,195 | 11,549 | 10,492 | 7,901 | (576) | 4,603 | 5,492 |
| Cash flow | |||||||
| Cash from operations | 6,501 | 4,252 | (292) | 507 | 7,636 | (417) | 1,306 |
| Cash from investing | (1,345) | (251) | (265) | (686) | (2,697) | 1,452 | 1,483 |
| Cash from financing | (5,230) | (3,836) | 474 | 169 | (4,871) | (1,000) | (2,871) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6,142 | 5,741 | 4,924 | 5,688 | 4,548 | 5,595 | 7,179 | 6,181 |
| Revenue growth (YoY) | +35.0% | +2.6% | -31.4% | -8.0% | -11.2% | +24.4% | - | - |
| Other income | 81.01 | 140 | 62.93 | 180 | 72.79 | 104 | 132 | 69.05 |
| Total expenses | 4,427 | 3,808 | 3,595 | 4,188 | 3,365 | 3,973 | 4,120 | 4,476 |
| EBITDA | 1,715 | 1,933 | 1,329 | 1,500 | 1,184 | 1,622 | 3,059 | 1,705 |
| EBITDA margin | +28.3% | +34.3% | +27.2% | +26.5% | +26.2% | +29.2% | +43.1% | +28.5% |
| Depreciation | 316 | 308 | 326 | 339 | 336 | 311 | 305 | 303 |
| Interest | 277 | 278 | 217 | 244 | 248 | 238 | 232 | 231 |
| Profit before tax | 1,203 | 1,486 | 849 | 1,097 | 672 | 1,176 | 2,654 | 1,240 |
| Tax | 332 | 371 | 240 | 392 | 108 | 431 | 612 | 83.81 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16,199 | 15,300 | 14,612 | 15,521 | 14,478 | 13,851 | 12,959 | 13,675 |
| Revenue growth (YoY) | +11.9% | +10.5% | +12.8% | +13.5% | +8.9% | +9.5% | - | - |
| Other income | 517 | 724 | 458 | 579 | 470 | 464 | 613 | 466 |
| EBITDA | 3,475 | 4,214 | 3,954 | 4,459 | 4,527 | 3,484 | 3,354 | 3,693 |
| EBITDA margin | +21.6% | +27.8% | +27.2% | +28.8% | +31.4% | +25.3% | +26.2% | +27.5% |
| Depreciation | 758 | 739 | 775 | 732 | 730 | 701 | 664 | 631 |
| Interest | 74.67 | 99.67 | 85.89 | 78.36 | 99.86 | 74.80 | 49.14 | 51.51 |
| Profit before tax | 3,159 | 4,099 | 3,551 | 4,227 | 4,168 | 3,173 | 3,254 | 3,476 |
| Tax | 1,158 | 1,188 | 828 | 826 | 1,031 | 870 | 1,094 | 559 |
| Net profit | 2,002 | 2,911 | 2,724 | 3,401 | 3,137 | 2,303 | 2,161 | 2,918 |
| EPS (₹) | 8.30 | 12.10 | 11.30 | 14.00 | 13.00 | 9.50 | 9.00 | 12.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 58,462 | 52,578 | 48,497 | 43,886 | 38,654 | 33,498 | 32,838 |
| Revenue growth | +11.2% | +8.4% | +10.5% | +13.5% | +15.4% | +2.0% | - |
| Other income | 3,212 | 2,151 | 1,390 | 635 | 1,075 | 859 | 652 |
| Total expenses | 43,278 | 38,170 | 36,004 | 32,410 | 32,978 | 29,337 | 26,124 |
| Employee cost | 11,419 | 9,973 | 9,429 | 8,296 | 7,301 | 6,862 | 6,362 |
| EBITDA | 15,184 | 14,408 | 12,493 | 11,475 | 5,677 | 4,162 | 6,714 |
| EBITDA margin | +26.0% | +27.4% | +25.8% | +26.2% | +14.7% | +12.4% | +20.4% |
| Depreciation | 2,938 | 2,575 | 2,557 | 2,529 | 2,144 | 2,080 | 2,053 |
| Interest | 339 | 231 | 238 | 172 | 127 | 141 | 303 |
| Profit before tax | 15,119 | 13,752 | 11,088 | 9,408 | 4,481 | 2,799 | 5,010 |
| Tax | 3,554 | 2,772 | 1,439 | 848 | 1,076 | 515 | 823 |
| Net profit | 12,429 | 11,456 | 9,990 | 8,605 | 6,717 | 5,728 | 3,961 |
| Net profit margin | +21.3% | +21.8% | +20.6% | +19.6% | +17.4% | +17.1% | +12.1% |
| EPS (₹) | 47.84 | 45.55 | 39.91 | 35.32 | 13.64 | 12.10 | 15.69 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
| Reserves & surplus | 83,330 | 71,978 | 63,427 | 55,755 | 47,771 | 46,223 | 45,025 |
| Shareholders' funds (net worth) | 83,570 | 72,218 | 63,667 | 55,995 | 48,011 | 46,463 | 45,264 |
| Minority interest | 310 | 268 | 3,459 | 3,320 | 3,055 | 3,017 | 3,860 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.83 | 257 |
| Unsecured loans | 4,627 | 2,362 | 3,274 | 6,886 | 1,290 | 3,861 | 8,057 |
| Total debt | 4,627 | 2,362 | 3,274 | 6,886 | 1,290 | 3,869 | 8,315 |
| Total liabilities | 90,020 | 75,718 | 71,314 | 67,131 | 53,376 | 54,447 | 58,774 |
| Assets | |||||||
| Gross block | 60,321 | 45,950 | 44,320 | 43,100 | 38,707 | 35,579 | 35,116 |
| Net block | 32,822 | 22,586 | 23,248 | 24,065 | 22,665 | 21,553 | 22,847 |
| Capital work in progress | 3,052 | 6,644 | 5,354 | 4,973 | 1,287 | 1,567 | 1,220 |
| Investments | 24,723 | 18,354 | 15,026 | 14,824 | 12,849 | 9,612 | 10,143 |
| Inventories | 11,493 | 10,243 | 9,868 | 10,513 | 8,925 | 8,997 | 7,875 |
| Sundry debtors | 15,510 | 13,046 | 11,249 | 11,439 | 10,485 | 9,061 | 9,421 |
| Cash & bank balances | 11,603 | 11,332 | 10,521 | 5,770 | 5,033 | 6,446 | 6,488 |
| Loans & advances | 4,321 | 4,317 | 3,210 | 2,767 | 2,788 | 2,808 | 2,973 |
| Total current assets | 42,927 | 38,938 | 34,849 | 30,489 | 27,231 | 27,312 | 26,757 |
| Total current liabilities | 18,388 | 16,190 | 14,014 | 13,580 | 16,400 | 13,175 | 9,420 |
| Net working capital | 24,539 | 22,748 | 20,835 | 16,909 | 10,831 | 14,137 | 17,336 |
| Total assets | 90,020 | 75,718 | 71,314 | 67,131 | 53,376 | 54,447 | 58,774 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 10,269 | 9,286 | 4,624 | 4,508 | 6,273 | 5,677 | 7,062 |
| Net cash from operating activities | 12,419 | 14,072 | 12,135 | 4,959 | 8,985 | 6,170 | 6,555 |
| Net cash from investing activities | (10,405) | (5,183) | (763) | (7,220) | (5,556) | 407 | (2,225) |
| Net cash from financing activities | (2,513) | (7,906) | (6,710) | 2,376 | (5,193) | (5,980) | (5,715) |
| Net change in cash | (498) | 983 | 4,662 | 115 | (1,765) | 596 | (1,386) |
| Closing cash | 11,603 | 11,332 | 10,521 | 5,770 | 5,033 | 6,446 | 6,488 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +11.2% | +8.4% | +10.5% | +13.5% | +15.4% | +2.0% | - |
| EBITDA growth | +5.4% | +15.3% | +8.9% | +102.1% | +36.4% | -38.0% | - |
| PBT growth | +9.9% | +24.0% | +17.9% | +110.0% | +60.1% | -44.1% | +31.5% |
| Net income growth | +8.5% | +14.7% | +16.1% | +28.1% | +17.3% | +44.6% | - |
| Revenue CAGR (3Y) | +10.0% | +10.8% | +13.1% | +10.2% | +10.0% | +8.1% | +1.3% |
| EBITDA CAGR (3Y) | +9.8% | +36.4% | +44.3% | +19.6% | +3.7% | -3.7% | -12.7% |
| Profitability & leverage | |||||||
| Net income margin | +19.8% | +20.9% | +19.9% | +19.5% | +8.8% | +6.8% | +12.8% |
| Return on capital employed | +18.7% | +19.5% | +17.2% | +16.8% | +18.0% | +13.6% | +9.9% |
| Return on net worth | +14.9% | +16.2% | +16.1% | +16.5% | +14.5% | +11.1% | +9.7% |
| Debt / equity | 0.04 | 0.04 | 0.08 | 0.08 | 0.05 | 0.13 | 0.22 |
| Long-term debt / equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.03 | 0.04 |
| Interest cover | 2.77 | 1.96 | 2.40 | 1.92 | 3.60 | 6.79 | 6.50 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.10 | 1.16 | 1.11 | 1.07 | 1.04 | 0.95 | 0.98 |
| Inventory turnover | 5.38 | 5.23 | 4.76 | 4.52 | 4.31 | 3.97 | 4.17 |
| Debtors turnover | 4.09 | 4.33 | 4.28 | 4.00 | 3.96 | 3.62 | 3.59 |
| EPS (₹) | 47.84 | 45.55 | 39.91 | 35.32 | 13.64 | 12.10 | 15.69 |
| Dividend per share (₹) | 16.00 | 16.00 | 13.50 | 11.50 | 10.00 | 7.50 | 4.00 |
| Book value per share (₹) | 348.31 | 301.00 | 265.36 | 233.38 | 200.11 | 193.65 | 188.66 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6,142 | 5,741 | 4,924 | 5,688 | 4,548 | 5,595 | 7,179 | 6,181 |
| Revenue growth (YoY) | +35.0% | +2.6% | -31.4% | -8.0% | -11.2% | +24.4% | - | - |
| Other income | 81.01 | 140 | 62.93 | 180 | 72.79 | 104 | 132 | 69.05 |
| Total expenses | 4,427 | 3,808 | 3,595 | 4,188 | 3,365 | 3,973 | 4,120 | 4,476 |
| EBITDA | 1,715 | 1,933 | 1,329 | 1,500 | 1,184 | 1,622 | 3,059 | 1,705 |
| EBITDA margin | +28.3% | +34.3% | +27.2% | +26.5% | +26.2% | +29.2% | +43.1% | +28.5% |
| Depreciation | 316 | 308 | 326 | 339 | 336 | 311 | 305 | 303 |
| Interest | 277 | 278 | 217 | 244 | 248 | 238 | 232 | 231 |
| Profit before tax | 1,203 | 1,486 | 849 | 1,097 | 672 | 1,176 | 2,654 | 1,240 |
| Tax | 332 | 371 | 240 | 392 | 108 | 431 | 612 | 83.81 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 20,755 | 22,977 | 20,275 | 20,812 | 15,586 | 14,116 | 12,532 |
| Revenue growth | -9.7% | +13.3% | -2.6% | +33.5% | +10.4% | +12.6% | - |
| Other income | 1,776 | 634 | 553 | 329 | 1,197 | 192 | 1,511 |
| Total expenses | 16,477 | 16,395 | 14,994 | 17,327 | 14,738 | 11,949 | 9,820 |
| Employee cost | 2,911 | 2,691 | 2,374 | 2,157 | 2,001 | 1,806 | 1,703 |
| EBITDA | 4,277 | 6,583 | 5,281 | 3,485 | 848 | 2,167 | 2,712 |
| EBITDA margin | +20.6% | +28.7% | +26.1% | +16.7% | +5.4% | +15.4% | +21.6% |
| Depreciation | 1,312 | 1,287 | 1,601 | 1,601 | 1,350 | 1,236 | 562 |
| Interest | 948 | 954 | 784 | 472 | 388 | 268 | 408 |
| Profit before tax | 3,794 | 4,976 | 3,450 | 1,741 | 307 | 856 | 3,253 |
| Tax | 1,171 | 748 | 591 | 50.33 | 407 | 13.17 | 41.86 |
| Net profit | 2,945 | 4,218 | 3,052 | 3,356 | (1,338) | 906 | 3,018 |
| Net profit margin | +14.2% | +18.4% | +15.1% | +16.1% | -8.6% | +6.4% | +24.1% |
| EPS (₹) | 10.93 | 17.62 | 11.91 | 7.05 | (0.42) | 3.51 | 13.38 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
| Reserves & surplus | 22,131 | 23,660 | 23,454 | 23,508 | 24,348 | 26,699 | 24,156 |
| Shareholders' funds (net worth) | 22,371 | 23,900 | 23,694 | 23,748 | 24,588 | 26,938 | 24,396 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.41 | 6.18 |
| Unsecured loans | 13,605 | 11,947 | 11,227 | 7,791 | 5,074 | 7,353 | 6,400 |
| Total debt | 13,605 | 11,947 | 11,227 | 7,791 | 5,074 | 7,358 | 6,406 |
| Total liabilities | 36,576 | 36,647 | 36,644 | 32,645 | 30,678 | 35,639 | 32,356 |
| Assets | |||||||
| Gross block | 20,681 | 19,200 | 18,252 | 17,745 | 17,195 | 15,812 | 8,245 |
| Net block | 7,613 | 7,372 | 7,737 | 8,712 | 9,713 | 9,669 | 5,229 |
| Capital work in progress | 899 | 1,084 | 766 | 853 | 829 | 1,090 | 597 |
| Investments | 12,952 | 12,410 | 12,430 | 12,613 | 15,549 | 15,537 | 17,362 |
| Inventories | 4,302 | 3,934 | 3,424 | 3,989 | 3,404 | 3,423 | 2,634 |
| Sundry debtors | 10,166 | 11,702 | 8,834 | 7,125 | 4,245 | 6,585 | 6,168 |
| Cash & bank balances | 437 | 911 | 338 | 421 | 535 | 361 | 655 |
| Loans & advances | 1,773 | 2,234 | 2,316 | 4,708 | 1,327 | 2,329 | 2,089 |
| Total current assets | 16,679 | 18,781 | 14,913 | 16,243 | 9,511 | 12,699 | 11,546 |
| Total current liabilities | 6,484 | 7,231 | 4,421 | 8,343 | 10,087 | 8,096 | 6,055 |
| Net working capital | 10,195 | 11,549 | 10,492 | 7,901 | (576) | 4,603 | 5,492 |
| Total assets | 36,576 | 36,647 | 36,644 | 32,645 | 30,678 | 35,639 | 32,356 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 493 | 327 | 410 | 420 | 351 | 315 | 303 |
| Net cash from operating activities | 6,501 | 4,252 | (292) | 507 | 7,636 | (417) | 1,306 |
| Net cash from investing activities | (1,345) | (251) | (265) | (686) | (2,697) | 1,452 | 1,483 |
| Net cash from financing activities | (5,230) | (3,836) | 474 | 169 | (4,871) | (1,000) | (2,871) |
| Net change in cash | (74.73) | 165 | (83.82) | (9.25) | 68.47 | 36.23 | (82.26) |
| Closing cash | 437 | 911 | 338 | 421 | 535 | 361 | 655 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -9.7% | +13.3% | -2.6% | +33.5% | +10.4% | +12.6% | - |
| EBITDA growth | -35.0% | +24.7% | +51.5% | +310.9% | -60.9% | -20.1% | - |
| PBT growth | -23.8% | +44.3% | +98.1% | +467.4% | -64.1% | -73.7% | +352.2% |
| Net income growth | -30.2% | +38.2% | -9.1% | +351.0% | -247.6% | -70.0% | - |
| Revenue CAGR (3Y) | -0.1% | +13.8% | +12.8% | +18.4% | +14.8% | +16.3% | +17.7% |
| EBITDA CAGR (3Y) | +7.1% | +98.0% | +34.6% | +8.7% | +16.1% | +327.4% | +187.6% |
| Profitability & leverage | |||||||
| Net income margin | +12.6% | +18.4% | +14.1% | +8.1% | -0.6% | +6.0% | +25.6% |
| Return on capital employed | +14.5% | +16.2% | +12.2% | +16.3% | +7.5% | +3.6% | +11.9% |
| Return on net worth | +12.7% | +17.8% | +12.1% | +13.9% | -5.2% | +3.5% | +13.6% |
| Debt / equity | 0.55 | 0.49 | 0.40 | 0.27 | 0.24 | 0.27 | 0.27 |
| Long-term debt / equity | 0.31 | 0.26 | 0.40 | 0.27 | 0.20 | 0.13 | 0.06 |
| Interest cover | 31.96 | 18.01 | 21.31 | 25.06 | -77.32 | 28.73 | 18.98 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.04 | 1.23 | 1.13 | 1.19 | 0.94 | 1.17 | 1.60 |
| Inventory turnover | 5.04 | 6.25 | 5.47 | 5.63 | 4.57 | 4.66 | 4.62 |
| Debtors turnover | 1.90 | 2.24 | 2.54 | 3.66 | 2.88 | 2.21 | 2.24 |
| EPS (₹) | 10.93 | 17.62 | 11.91 | 7.05 | (0.42) | 3.51 | 13.38 |
| Dividend per share (₹) | 16.00 | 16.00 | 13.50 | 11.50 | 10.00 | 7.50 | 4.00 |
| Book value per share (₹) | 93.24 | 99.61 | 98.76 | 98.98 | 102.48 | 112.28 | 101.68 |
Similar companies to Shubham Pharmaceutical
Shubham Pharmaceutical has 3 listed similar companies in our database, 3 of them funded. They include Entero Healthcare, Keimed and Sandor Medicaids.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| enterohealthcare.com | 2018 | Mumbai, India | $59.67M | 817 | India's leading healthcare products distribution platform | |
| keimed.com | 2000 | Hyderabad, India | $16.62M | 588 | Temperature-sensitive medicines are distributed via cold chain logistics by Keimed. | |
| sandor.co.in | 1995 | Hyderabad, India | $8.98M | 161 | Provider of medical equipment, devices, and drugs distribution services |
Detailed similar companies of Shubham Pharmaceutical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Shubham Pharmaceutical
Shubham Pharmaceutical was founded in 2006.
Shubham Pharmaceutical is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
The primary company behind Shubham Pharmaceutical, Sun Pharmaceutical Industries Limited, reported revenue of ₹61,674 Cr for FY 2026, up 11% year on year.
Shubham Pharmaceutical, founded in 2006 in Mumbai, India, focuses on providing healthcare solutions, producing pharmaceutical products, distribution, and drug supply. Serves as a distributor of a wide range of pharmaceutical drugs. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Shubham Pharmaceutical's top competitors include Entero Healthcare, Keimed and Sandor Medicaids.
Yes, Shubham Pharmaceutical is publicly traded on NSE under the ticker symbol SUNPHARMA.
Shubham Pharmaceutical operates through Sun Pharmaceutical Industries Limited.
The legal entities of Shubham Pharmaceutical currently have 10 directors, including Pawan Kumar Goenka, Anoop Anjanikumar Deshpande, Dilip Shantilal Shanghvi and others.